aTyr Pharma granted additional 180-day period to cure minimum bid price deficiency
aTyr Pharma received notice on June 3, 2026 that it has until November 30, 2026 to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company had previously received a deficiency notice on December 4, 2025 with an initial June 2, 2026 compliance deadline. Nasdaq determined the company met other continued listing standards and is eligible for the extended compliance period, during which the company may effect a reverse stock split if necessary.
Key facts
- aTyr Pharma Inc received deficiency notice on December 4, 2025
- Common stock closing bid price fell below $1.00 per share for 30 consecutive business days
- Initial compliance deadline: June 2, 2026
- Company received extension letter on June 3, 2026
- Extended compliance deadline (Compliance Date): November 30, 2026
- Nasdaq Listing Rule 5550(a)(2) minimum closing bid price requirement: $1.00 per share
- Company stated intention to cure deficiency by effecting reverse stock split, if necessary
Why it matters
The extended compliance period provides aTyr Pharma additional time to reverse a sustained decline in stock price, though failure to meet the November 30, 2026 deadline would trigger a delisting determination from which the company could appeal.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-08. Not investment advice. View the source filing on SEC.gov →